• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 4. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 5. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives Chlorinated biphenyls

Introduction to 2-(3-Chlorophenyl)-5-methoxybenzoic acid (CAS No. 1261929-14-9)

2-(3-Chlorophenyl)-5-methoxybenzoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1261929-14-9, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This benzoic acid derivative exhibits a unique structural configuration characterized by the presence of a chloro substituent at the 3-position of the phenyl ring and a methoxy group at the 5-position. Such structural features make it a valuable scaffold for the development of novel therapeutic agents, particularly in addressing various biological targets and diseases.

The compound's molecular formula, C₁₃H₉ClO₃, underscores its aromatic nature and the presence of multiple functional groups that contribute to its reactivity and potential biological activity. The chloro group introduces electrophilic characteristics, while the methoxy group provides resonance stabilization and influences the overall electronic distribution across the molecule. These features are critical in determining its interaction with biological targets, such as enzymes and receptors, which are pivotal in drug design.

In recent years, 2-(3-Chlorophenyl)-5-methoxybenzoic acid has garnered attention in academic and industrial research due to its potential pharmacological properties. Studies have demonstrated its utility as an intermediate in synthesizing more complex molecules with targeted biological activities. For instance, researchers have explored its role in developing inhibitors for enzymes involved in inflammatory pathways, such as cyclooxygenase (COX) and lipoxygenase (LOX). These enzymes are key players in mediating inflammatory responses, making them attractive targets for therapeutic intervention.

The benzoic acid core is a well-established motif in medicinal chemistry, known for its broad spectrum of biological activities. Derivatives of benzoic acid have been widely investigated for their antimicrobial, anti-inflammatory, and analgesic properties. The introduction of electron-withdrawing groups like the chloro substituent enhances the compound's binding affinity to biological targets, while the methoxy group modulates its metabolic stability and pharmacokinetic profile. This balance makes 2-(3-Chlorophenyl)-5-methoxybenzoic acid a promising candidate for further optimization into a lead compound.

Recent advancements in computational chemistry and high-throughput screening have accelerated the discovery process for novel drug candidates. Computational models have been employed to predict the binding interactions of 2-(3-Chlorophenyl)-5-methoxybenzoic acid with various protein targets, providing insights into its potential mechanism of action. These studies have revealed that the compound exhibits favorable binding affinities with several enzymes and receptors implicated in metabolic disorders, cancer, and neurodegenerative diseases.

The synthesis of 2-(3-Chlorophenyl)-5-methoxybenzoic acid involves multi-step organic transformations that highlight its synthetic versatility. Traditional methods include Friedel-Crafts acylation followed by selective functional group modifications to introduce the chloro and methoxy groups. Alternatively, modern synthetic approaches leverage transition metal-catalyzed cross-coupling reactions to construct the desired aromatic core efficiently. These advancements in synthetic methodology have not only improved yield but also reduced environmental impact, aligning with green chemistry principles.

In clinical research, 2-(3-Chlorophenyl)-5-methoxybenzoic acid has been evaluated in preclinical models for its potential therapeutic applications. Preliminary studies suggest that it may exhibit anti-inflammatory effects comparable to existing nonsteroidal anti-inflammatory drugs (NSAIDs) but with improved selectivity and reduced side effects. Additionally, its ability to modulate oxidative stress pathways has prompted investigations into its potential role in neuroprotective therapies against conditions such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic profile of 2-(3-Chlorophenyl)-5-methoxybenzoic acid is another critical aspect that has been extensively studied. Absorption studies indicate that it is well-absorbed following oral administration, with bioavailability comparable to other benzoic acid derivatives. Metabolic stability studies have revealed that it undergoes conjugation with glucuronic acids and sulfate ions, facilitating renal excretion. This suggests that it may exhibit a moderate half-life, allowing for once or twice daily dosing regimens in clinical settings.

The safety profile of 2-(3-Chlorophenyl)-5-methoxybenzoic acid has also been assessed through toxicological studies conducted on cell cultures and animal models. These studies have shown that it exhibits low toxicity at therapeutic doses, with minimal evidence of organ toxicity or carcinogenicity. However, further long-term studies are warranted to fully characterize its safety profile before human clinical trials can commence.

The future direction of research on 2-(3-Chlorophenyl)-5-methoxybenzoic acid lies in optimizing its chemical structure to enhance potency, selectivity, and pharmacokinetic properties. Strategies such as structure-activity relationship (SAR) studies and molecular modeling will be instrumental in identifying key structural determinants responsible for its biological activity. Additionally, exploring novel synthetic routes to improve scalability will be crucial for industrial production.

In conclusion,2-(3-Chlorophenyl)-5-methoxybenzoic acid (CAS No. 1261929-14-9) represents a promising compound with significant potential in pharmaceutical development. Its unique structural features make it an attractive scaffold for designing novel therapeutics targeting various diseases. With ongoing research efforts focused on optimizing its pharmacological properties and synthetic accessibility,2-(3-Chlorophenyl)-5-methoxybenzoic acid is poised to contribute substantially to advancements in medicinal chemistry and drug discovery.

• 70109-47-6(3-Phenanthrenecarboxylic acid,4-(4-chlorophenyl)-1-hydroxy-9-methoxy-)
• 1261906-78-8(4-chloro-2-(3-phenylmethoxyphenyl)benzoic Acid)
• 1261974-52-0(2-(2-chloro-5-methoxyphenyl)benzoic Acid)
• 1261999-80-7(2-(2-chloro-5-methoxyphenyl)-5-methylbenzoic Acid)
• 1261927-69-8(2-(2-chloro-5-methoxyphenyl)-5-methoxybenzoic Acid)
• 1261932-17-5(4-chloro-2-(3-ethoxyphenyl)benzoic Acid)
• 1262007-54-4(2-(4-chloro-3-methylphenyl)-5-methoxybenzoic Acid)
• 537713-41-0(2-(4-chlorophenyl)-5-methoxybenzoic Acid)
• 537715-60-9([1,1'-Biphenyl]-2-carboxylic acid, 4'-chloro-4-ethoxy-)
• 70109-53-4(3-Phenanthrenecarboxylic acid, 4-(4-chlorophenyl)-1,9-dimethoxy-)